Home › Core › ISCC-IDs › 28C8H8T18tNXM

View ISCC-ID

Core Data

28C8H8T18tNXM
ISCC-ID - digital asset identifier
CCfTiZeELhB4D-CT4823ZWFM4gK-CDDoUcSdBcyHz-CRP99LTWzdvty
ISCC-CODE - digital asset descriptor
2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd
PUBLIC-KEY or WALLET-ADDRESS of DECLARING PARTY
0
Number of times updated

Seed Metadata (Immutable)

clinical trial of the protein farnesylation inhibitors lonafarnib pravastatin and zoledronic acid in children with hutchinsongil

Ledger Reference

coblo
Source Ledger/Blockchain
11182
N-th ISCC Decleration on source ledger
2d19a497ef30126b004fddf169449088616c3c0e66274598ed256aebcdd14ed8
Hash of block that includes the ISCC-DECLARATION
c59ebecf18a9f563aaeceb3654e5a6921570bcf8469578660a10c714f3d2f54e
Hash of transaction that includes the ISCC-DECLERATION
0
Output index that includes ISCC-DECLERATION (UTXO based chains)

Mutable Metadata

[{"data": {"name": "Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria SyndromeClinical Perspective", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "Leslie B. Gordon", "@type": "Person"}, {"name": "Monica E. Kleinman", "@type": "Person"}, {"name": "Joe Massaro", "@type": "Person"}, {"name": "Ralph B. D\u2019Agostino", "@type": "Person"}, {"name": "Heather Shappell", "@type": "Person"}, {"name": "Marie Gerhard-Herman", "@type": "Person"}, {"name": "Leslie B. Smoot", "@type": "Person"}, {"name": "Catherine M. Gordon", "@type": "Person"}, {"name": "Robert H. Cleveland", "@type": "Person"}, {"name": "Ara Nazarian", "@type": "Person"}, {"name": "Brian D. Snyder", "@type": "Person"}, {"name": "Nicole J. Ullrich", "@type": "Person"}, {"name": "V. Michelle Silvera", "@type": "Person"}, {"name": "Marilyn G. Liang", "@type": "Person"}, {"name": "Nicolle Quinn", "@type": "Person"}, {"name": "David T. Miller", "@type": "Person"}, {"name": "Susanna Y. Huh", "@type": "Person"}, {"name": "Anne A. Dowton", "@type": "Person"}, {"name": "Kelly Littlefield", "@type": "Person"}, {"name": "Maya M. Greer", "@type": "Person"}, {"name": "Mark W. Kieran", "@type": "Person"}], "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "http://europepmc.org/articles/pmc4943677?pdf=render", "encodingFormat": "application/pdf"}], "publisher": {"name": "Ovid Technologies (Wolters Kluwer Health)", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.1161/circulationaha.116.022188", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCfTiZeELhB4D-CT4823ZWFM4gK-CDDoUcSdBcyHz-CRP99LTWzdvty", "propertyID": "ISCC"}], "datePublished": "2016-07-08"}, "schema": "schema.org", "mediatype": "application/ld+json"}]
Close